Skip to main content

Advertisement

SpringerLink
Log in

Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC)

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Background

This study was conducted using irinotecan and cisplatin (IP) concurrently with thoracic radiation therapy to evaluate the response and toxicity of this protocol in the treatment of patients with limited-disease small cell lung cancer (LD-SCLC).

Methods

Twenty-seven chemotherapy-naive patients with LD-SCLC received two cycles of weekly irinotecan 60 mg/m2 and cisplatin 60 mg/m2 before the initiation of the thoracic radiation therapy.

Results

Of the 29 patients with LD-SCLC enrolled in the study, 27 were eligible for evaluation of response and toxicity. The median age was 62 years; 26 patients (90%) were men. Eastern Cooperative Oncology Group (ECOG) performance status was 0 in 5 patients (17%) and 1 in 18 patients (62%). Ten patients (37%) achieved a complete response (CR), 14 patients (52%) achieved a partial response (PR), while 3 patients (11%) had progressive disease (PD); one of the 3 nonresponders achieved a PR after commencing concurrent chemoradiotherapy; therefore, the overall response rate was 93%. The median survival time was 20.2 months and 1- and 2-year survival rates were 69% and 53.2%, respectively. The median progression-free survival (PFS) was 11.8 months, and 1- and 2-year PFS times were 52% and 34.1%, respectively. Neutropenia was the most prevalent hematological toxicity and it was evident as grade 3 in 14 patients (52%). Asthenia was the most prevalent nonhematological toxicity, in 18 patients (67%); esophagitis occurred in 15 patients (56%). No treatment-related deaths (due to sepsis or bleeding) were reported in the study.

Conclusion

Irinotecan and cisplatin is considered to be an effective and safe chemotherapeutic regimen when used concurrently with thoracic radiation therapy for the treatment of patients with LD-SCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sekine I, Nishiwaki Y, Noda K, et al. (2003) Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI). Ann Oncol 14:709–714

    Article  PubMed  CAS  Google Scholar 

  2. Murray N (1997) Treatment of small cell lung cancer: the state of the art. Lung Cancer 17:S75–S89

    Article  PubMed  Google Scholar 

  3. Mountain CF (1987) Staging of lung cancer: the new international system. Lung Cancer 3:4–11

    Article  Google Scholar 

  4. Rosti G, Bevilacqua G, Bidoli P, et al. (2006) Small cell lung cancer. Ann Oncol 17(Suppl 2):ii5–ii10

    Article  PubMed  Google Scholar 

  5. Kurup A, Hanna NH (2004) Treatment of small cell lung cancer. Crit Rev Oncol Hematol 52:117–126

    Article  PubMed  Google Scholar 

  6. Lassen U, Hansen HH (1999) Surgery in limited stage small cell lung cancer. Cancer Treat Rev 25:67–72

    Article  PubMed  CAS  Google Scholar 

  7. Kubota K, Nishiwaki Y, Sugiura T, et al. (2005) Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903. Clin Cancer Res 11:5534–5538

    Article  PubMed  CAS  Google Scholar 

  8. Han JY, Cho KH, Lee DH, et al. (2005) Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer. J Clin Oncol 23:3488–3494

    Article  PubMed  CAS  Google Scholar 

  9. Fried DB, Morris DE, Poole C (2004) Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22:4837–4845

    Article  PubMed  Google Scholar 

  10. Ohe Y (2002) Treatment-related death from chemotherapy and thoracic radiotherapy for advanced cancer. Panminerva Med 44:205–212

    PubMed  CAS  Google Scholar 

  11. Ettinger DS (2001) New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer. Semin Oncol 28: S27–S29

    Article  Google Scholar 

  12. Kudoh S, Fujiwara Y, Takada Y, et al. (1998) Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 16:1068–1074

    PubMed  CAS  Google Scholar 

  13. Noda K, Nishiwaki Y, Kawahara M, et al. (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 346:85–91

    Article  PubMed  CAS  Google Scholar 

  14. Fukuda M, Nishio K, Kanzawa F, et al. (1996) Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res 56:789–793

    PubMed  CAS  Google Scholar 

  15. Tamura K, Takada M, Kawase I, et al. (1997) Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts. Jpn J Cancer Res 88:218–223

    PubMed  CAS  Google Scholar 

  16. Kudoh S, Nakamura S, Nakano T, et al. (2005) Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group. Lung Cancer 49:263–269

    Article  PubMed  CAS  Google Scholar 

  17. Hanna N, Bunn PA Jr, Langer C, et al. (2006) Randomised phase III trial comparing irinotecan/cisplatin with etoposide/ cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24:2038–2043

    Article  PubMed  CAS  Google Scholar 

  18. Schmittel A, von Weikersthal LF, Sebastian M, et al. (2006) A randomised phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol 17:663–667

    Article  PubMed  CAS  Google Scholar 

  19. Auperin A, Arriagada R, Pignon JP, et al. (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission: Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341:476–484

    Article  PubMed  CAS  Google Scholar 

  20. Gregor A, Drings P, Burghouts J, et al. (1997) Randomized trial of alternating versus sequential radiotherapy/chemotherapy in limited-disease patients with small-cell lung cancer: a European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group Study. J Clin Oncol 15:2840–2849

    PubMed  CAS  Google Scholar 

  21. WHO (1979) WHO Handbook for reporting results of cancer treatment. WHO, Geneva

    Google Scholar 

  22. Oken MM, Creech RH, Tormey DC, et al. (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649–655

    Article  PubMed  CAS  Google Scholar 

  23. Byhardt RW, Martin L, Pajak TF (1993) The influence of field size and other treatment factors on pulmonary toxicity following hyperfractionated irradiation for inoperable non-small-cell lung cancer (NSCLC) — analysis of a Radiation Therapy Oncology Group (RTOG) protocol. Int J Radiat Oncol Biol Phys 27:537–544

    PubMed  CAS  Google Scholar 

  24. Kaplan ES, Meier P (1958) Non-parametric estimation from incomplete observation. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  25. Oka M, Fukuda M, Kuba M, et al. (2002) Phase I study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small-cell lung cancer. Eur J Cancer 38:1998–2004

    PubMed  CAS  Google Scholar 

  26. Klautke G, Fähndrich S, Semrau S, et al. (2006) Simultaneous chemoradiotherapy with irinotecan and cisplatin in limited disease small cell lung cancer: a phase I study. Lung Cancer 53:183–188

    Article  PubMed  Google Scholar 

  27. Turrisi AT 3rd, Kim K, Blum R, et al. (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265–271

    Article  PubMed  CAS  Google Scholar 

  28. Jeong HC, Lee SY, Lee SY, et al. (2006) Phase II study of irinotecan plus cisplatin with concurrent radiotherapy for the patients with limited-disease small-cell lung cancer. Lung Cancer 53: 361–366

    Article  PubMed  Google Scholar 

  29. Sohn JH, Moon JW, Lee CG, et al. (2007) Phase II trial of irinotecan and cisplatin with early concurrent radiotherapy in limited-disease small-cell lung cancer. Cancer 109:1845–1850

    Article  PubMed  CAS  Google Scholar 

  30. Glisson B, Scott C, Komaki R, et al. (2000) Cisplatin, ifosfamide, oral etoposide, and concurrent accelerated hyperfractionated thoracic radiation for patients with limited small-cell lung carcinoma: results of Radiation Therapy Oncology Group Trial 93–12. J Clin Oncol 18:2990–2995

    PubMed  CAS  Google Scholar 

  31. Takada M, Fukuoka M, Kawahara M, et al. (2002) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small cell lung cancer: results of the Japan Clinical Oncology Group Study 9104. J Clin Oncol 20:3054–3060

    Article  PubMed  CAS  Google Scholar 

  32. Schild SE, Bonner JA, Shanahan TG, et al. (2004) Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 59:943–951

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology and Radiotherapy, Ain Shams University, Cairo, Egypt

    Sherif Abdelwahab, Hatem Abdulla, Ali Azmy, Ahmed Abdelfatah, Hany Abdel-Aziz, Maha Margerges & Atef Riad

  2. Department of Radiation Oncology, Johannesburg Hospital and University of Witwatersrand, Johannesburg, South Africa

    Vinay Sharma

  3. Department of Chest Diseases, Ain Shams University, Cairo, Egypt

    Ibrahim Dwedar

  4. 28 Elfareek Mohamed Ibrahim Street, Nasr City, Cairo, Egypt

    Sherif Abdelwahab

Authors
  1. Sherif Abdelwahab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hatem Abdulla
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ali Azmy
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ahmed Abdelfatah
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hany Abdel-Aziz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maha Margerges
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Atef Riad
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Vinay Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ibrahim Dwedar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sherif Abdelwahab.

About this article

Cite this article

Abdelwahab, S., Abdulla, H., Azmy, A. et al. Integration of irinotecan and cisplatin with early concurrent conventional radiotherapy for limited-disease SCLC (LD-SCLC). Int J Clin Oncol 14, 230–236 (2009). https://doi.org/10.1007/s10147-008-0842-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-008-0842-7

Key words

Search

Navigation